Loading cancer entity…
Loading cancer entity…
Clinical trials
972 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (145)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00343564 | A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 68 | CytokineticsINDUSTRY | 2 | Jan 13, 2020 | clinicaltrials |
| NCT00481871 | Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies | completed | Phase 1 / Phase 2 | 119 | Acrotech Biopharma Inc.INDUSTRY | 1 | Jan 7, 2020 | clinicaltrials |
| NCT01527045 |
| Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies |
| completed |
| Phase 2 |
| 47 |
| Fred Hutchinson Cancer CenterOTHER |
| 1 |
| Jan 2, 2020 |
| clinicaltrials |
| NCT00723099 | Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer | completed | Phase 2 | 73 | Fred Hutchinson Cancer CenterOTHER | 1 | Dec 27, 2019 | clinicaltrials |
| NCT00027820 | Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | completed | Phase 1 / Phase 2 | 106 | Fred Hutchinson Cancer CenterOTHER | 3 | Dec 20, 2019 | clinicaltrials |
| NCT00013533 | Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies | completed | Early Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2019 | clinicaltrials |
| NCT01326702 | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | completed | Phase 1 / Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2019 | clinicaltrials |
| NCT01251575 | Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | completed | Phase 2 | 77 | Fred Hutchinson Cancer CenterOTHER | 2 | Dec 9, 2019 | clinicaltrials |
| NCT00185692 | Allogeneic Transplantation From Related Haploidentical Donors | completed | Phase 2 | 16 | Stanford UniversityOTHER | 1 | Dec 4, 2019 | clinicaltrials |
| NCT00652626 | Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function(RENAL) | completed | Phase 1 | 31 | CelgeneINDUSTRY | 1 | Nov 19, 2019 | clinicaltrials |
| NCT02719821 | Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation | completed | N/A | 17 | University of Wisconsin, MadisonOTHER | 1 | Nov 15, 2019 | clinicaltrials |
| NCT02955043 | Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery | completed | N/A | 39 | University of Wisconsin, MadisonOTHER | 1 | Nov 15, 2019 | clinicaltrials |
| NCT00856388 | Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders | completed | N/A | 62 | Roswell Park Cancer InstituteOTHER | 1 | Nov 13, 2019 | clinicaltrials |
| NCT01453504 | Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma(HD-R3i) | completed | Phase 1 / Phase 2 | 73 | University of CologneOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT01660776 | BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology(BMS_PD-L1) | completed | — | 105 | Rennes University HospitalOTHER | 1 | Nov 6, 2019 | clinicaltrials |
| NCT00105001 | Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 210 | Fred Hutchinson Cancer CenterOTHER | 3 | Oct 30, 2019 | clinicaltrials |
| NCT01076543 | Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 110 | National Cancer Institute (NCI)NIH | 1 | Oct 16, 2019 | clinicaltrials |
| NCT02164006 | Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients | completed | Phase 1 | 16 | TG Therapeutics, Inc.INDUSTRY | 1 | Oct 2, 2019 | clinicaltrials |
| NCT01529827 | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 94 | Roswell Park Cancer InstituteOTHER | 1 | Sep 24, 2019 | clinicaltrials |
| NCT00005799 | Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | completed | N/A | 55 | Fred Hutchinson Cancer CenterOTHER | 2 | Sep 10, 2019 | clinicaltrials |
| NCT01839916 | Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 77 | University of ChicagoOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT02389101 | Molecular and Whole-body MR Imaging in Lymphomas(MILY) | completed | N/A | 21 | Turku University HospitalOTHER_GOV | 1 | Aug 5, 2019 | clinicaltrials |
| NCT04028804 | FLT PET: A Pilot Study in Lymphoma Patients | completed | — | 8 | The Hospital for Sick ChildrenOTHER | 1 | Jul 23, 2019 | clinicaltrials |
| NCT01008462 | Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia | completed | Phase 2 | 16 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 11, 2019 | clinicaltrials |
| NCT02665650 | Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | completed | Phase 1 | 30 | Affimed GmbHINDUSTRY | 2 | May 16, 2019 | clinicaltrials |
| NCT00165412 | Breast MRI Screening in Women Treated With Mediastinal Irradiation for Hodgkin's Disease | completed | — | 148 | Dana-Farber Cancer InstituteOTHER | 1 | May 2, 2019 | clinicaltrials |
| NCT02243436 | Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 67 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Apr 24, 2019 | clinicaltrials |
| NCT00900250 | Collecting and Storing Biological Samples From Young Patients With Hodgkin?s Lymphoma | completed | — | 1,271 | Children's Oncology GroupNETWORK | 4 | Apr 10, 2019 | clinicaltrials |
| NCT00802113 | Autologous and Allogeneic Transplant for Relapsed Lymphoma | completed | Phase 1 / Phase 2 | 30 | Columbia UniversityOTHER | 1 | Mar 27, 2019 | clinicaltrials |
| NCT00520130 | Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System | completed | Phase 1 / Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2019 | clinicaltrials |
| NCT01874054 | Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 55 | Seagen Inc.INDUSTRY | 1 | Feb 12, 2019 | clinicaltrials |
| NCT00928018 | Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma | completed | Phase 3 | 139 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 1, 2019 | clinicaltrials |
| NCT00850200 | Proton Therapy for Hodgkin Lymphoma(HL01) | completed | N/A | 20 | University of FloridaOTHER | 1 | Jan 31, 2019 | clinicaltrials |
| NCT01897012 | Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas | completed | Phase 1 | 26 | National Cancer Institute (NCI)NIH | 1 | Jan 28, 2019 | clinicaltrials |
| NCT01408563 | Reduced Intensity Double Umbilical Cord Blood Transplantation | completed | Phase 2 | 33 | Massachusetts General HospitalOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT02208037 | Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) | completed | Phase 2 | 279 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jan 23, 2019 | clinicaltrials |
| NCT01634217 | Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation | completed | Phase 1 | 16 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 18, 2019 | clinicaltrials |
| NCT02240719 | Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer | completed | Phase 1 | 20 | University of California, DavisOTHER | 1 | Jan 4, 2019 | clinicaltrials |
| NCT01702961 | Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease(Rituxan+BEAM) | completed | N/A | 75 | Baylor College of MedicineOTHER | 1 | Dec 19, 2018 | clinicaltrials |
| NCT01165112 | Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma(TREC) | completed | Phase 1 / Phase 2 | 48 | University of WashingtonOTHER | 1 | Dec 5, 2018 | clinicaltrials |
| NCT01393106 | Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma | completed | Phase 2 | 25 | Gilead SciencesINDUSTRY | 1 | Nov 19, 2018 | clinicaltrials |
| NCT00709592 | Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT | completed | Phase 2 | 42 | Virginia Commonwealth UniversityOTHER | 1 | Nov 9, 2018 | clinicaltrials |
| NCT01499147 | Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies | completed | N/A | 100 | University of Illinois at ChicagoOTHER | 1 | Nov 8, 2018 | clinicaltrials |
| NCT01965119 | Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma(JAK2) | completed | Phase 2 | 20 | Samsung Medical CenterOTHER | 1 | Nov 1, 2018 | clinicaltrials |
| NCT00038558 | Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy | completed | Phase 3 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT01569204 | Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma | completed | Phase 2 | 100 | University of CologneOTHER | 1 | Oct 29, 2018 | clinicaltrials |
| NCT00896454 | Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium | completed | Phase 2 | 33 | AmgenINDUSTRY | 5 | Oct 17, 2018 | clinicaltrials |
| NCT01342289 | Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide | completed | Phase 1 | 127 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 17, 2018 | clinicaltrials |
| NCT03323541 | Use of Zarzio® in Post-autologous Stem Cell Transplantation Procedure(ZAPA) | completed | — | 62 | University Hospital, BrestOTHER | 0 | Sep 21, 2018 | clinicaltrials |
| NCT03107663 | ⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma | completed | Phase 1 | 15 | ImaginAb, Inc.INDUSTRY | 1 | Sep 18, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Jan 13, 2020source: clinicaltrials